Literature DB >> 15380530

Distinct subpopulations of gamma delta T cells are present in normal and tumor-bearing human liver.

Tony Kenna1, Lucy Golden-Mason, Suzanne Norris, John E Hegarty, Cliona O'Farrelly, Derek G Doherty.   

Abstract

Gamma delta T cells are thought to mediate immune responses at epithelial surfaces. We have quantified and characterized hepatic and peripheral blood gamma delta T cells from 11 normal and 13 unresolved tumor-bearing human liver specimens. gamma delta T cells are enriched in normal liver (6.6% of T cells) relative to matched blood (0.9%; P = 0.008). The majority express CD4(-)CD8(-) phenotypes and many express CD56 and/or CD161. In vitro, hepatic gamma delta T cells can be induced to kill tumor cell lines and release interferon-gamma, tumor necrosis factor-alpha, interleukin-2 and interleukin-4. Analysis of V gamma and V delta chain usage indicated that V delta 3(+) cells are expanded in normal livers (21.2% of gamma delta T cells) compared to blood (0.5%; P = 0.001). Tumor-bearing livers had significant expansions and depletions of gamma delta T cell subsets but normal cytolytic activity. This study identifies novel populations of liver T cells that may play a role in immunity against tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380530     DOI: 10.1016/j.clim.2004.05.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  42 in total

Review 1.  Innate T cells in the intensive care unit.

Authors:  Edy Yong Kim; William M Oldham
Journal:  Mol Immunol       Date:  2018-12-13       Impact factor: 4.407

2.  The murine CD94/NKG2 ligand, Qa-1b, is a high-affinity, functional ligand for the CD8αα homodimer.

Authors:  Katharine Jennifer Goodall; Angela Nguyen; Craig McKenzie; Sidonia Barbara Guiomar Eckle; Lucy Catherine Sullivan; Daniel Mark Andrews
Journal:  J Biol Chem       Date:  2020-01-28       Impact factor: 5.157

3.  Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells.

Authors:  Bozgana A Mangan; Margaret R Dunne; Vincent P O'Reilly; Pádraic J Dunne; Mark A Exley; Donal O'Shea; Emmanuel Scotet; Andrew E Hogan; Derek G Doherty
Journal:  J Immunol       Date:  2013-06-05       Impact factor: 5.422

4.  Human Hepatic CD56bright NK Cells Display a Tissue-Resident Transcriptional Profile and Enhanced Ability to Kill Allogenic CD8+ T Cells.

Authors:  Gráinne Jameson; Cathal Harmon; Rhyla Mae Santiago; Diarmaid D Houlihan; Tom K Gallagher; Lydia Lynch; Mark W Robinson; Cliona O'Farrelly
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

5.  Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma.

Authors:  Kia Joo Puan; John Seng Hooi Low; Terence Wee Kiat Tan; Joseph Tien Seng Wee; Eng Huat Tan; Kam Weng Fong; Eu Tiong Chua; Chenggang Jin; José-Luis Giner; Craig T Morita; Christopher Hood Keng Goh; Kam M Hui
Journal:  Cancer Immunol Immunother       Date:  2008-11-30       Impact factor: 6.968

Review 6.  Microanatomy of the liver immune system.

Authors:  Eszter Nemeth; Alan W Baird; Cliona O'Farrelly
Journal:  Semin Immunopathol       Date:  2009-07-29       Impact factor: 9.623

Review 7.  Role of gamma-delta T cells in liver inflammation and fibrosis.

Authors:  Linda Hammerich; Frank Tacke
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

8.  Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities.

Authors:  Elena Lo Presti; Francesco Dieli; Serena Meraviglia
Journal:  Vaccines (Basel)       Date:  2021-05-28

Review 9.  Stress kinases in the development of liver steatosis and hepatocellular carcinoma.

Authors:  Beatriz Cicuéndez; Irene Ruiz-Garrido; Alfonso Mora; Guadalupe Sabio
Journal:  Mol Metab       Date:  2021-02-13       Impact factor: 7.422

10.  Oenothein B, a cyclic dimeric ellagitannin isolated from Epilobium angustifolium, enhances IFNγ production by lymphocytes.

Authors:  Andrew G Ramstead; Igor A Schepetkin; Mark T Quinn; Mark A Jutila
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.